Tempus AI reported a 22% revenue increase in Q2 2026, improved profit margins, and raised its full-year guidance despite ongoing operating losses. The company’s acquisition of Personalis addresses a crucial gap in minimal residual disease (MRD) monitoring, enabling recurring revenue and enhancing its AI data capabilities. While competition in the MRD space remains intense, Tempus AI’s strong cash reserves, growing oncology testing volumes, and planned future partnerships position it well for long-term growth. These strategic moves have encouraged investors to increase their holdings in the company.
Tempus AI trades at USD 77.97 on Pluang as of Sep 22, 2026, 18:21 WIB, showing a slight 0.08% decline in one day. The stock's market cap stands at $14.17 billion, with a 52-week high of $103.25 and low of $41.55. Pluang investors hold the stock for an average of 22 days, with 99% of recent orders being buys, reflecting strong buying interest despite minor price dips.
Tempus AI's stock surged 60%, fueled by a 31% year-over-year increase in oncology testing volumes and nearly doubled MRD test volumes since Q4 2025, validating its acquisition of Personalis. The company's data and applications segment grew 28% in Q2,...
Tempus AI's stock surged 29% in one week, driven by positive analyst commentary and new revenue prospects from reimbursement changes. Goldman Sachs initiated coverage with a Neutral rating and a $75 price target, while technical indicators like a tri...
Tempus AI shares surged nearly 30% this week following Morgan Stanley's optimistic revenue forecast driven by clearer reimbursement pricing for its diagnostic products. CEO Eric Lefkofsky highlighted potential revenue increases of $80-$100 million fr...
